Key result
Sacubitril/valsartan plus anti-rheumatic therapy resolves myocardial inflammation and improves biventricular EF in giant cell arteritis.
Why the study?
Myocardial inflammation in giant cell arteritis and its detection by cardiovascular magnetic resonance is not well characterized.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
We describe a patient with GCA and cardiac involvement, presented as myocardial inflammation with reduced biventricular ejection fraction and diagnosed using cardiovascular magnetic resonance (CMR). She was treated successfully with sacubitril/valsartan in parallel with anti-rheumatic medication and the post-treatment CMR showed improvement of biventricular function and disappearance of myocardial inflammation.
No takes yet. Share an insight, caveat, or question.
Mavrogeni et al. (2021) conducted a case report in Giant cell arteritis with myocardial inflammation (myocarditis) (n=1). Sacubitril/valsartan and anti-rheumatic medication (corticosteroids, tocilizumab) was evaluated on Myocardial inflammation and biventricular function on CMR. Treatment with sacubitril/valsartan and anti-rheumatic therapy successfully resolved myocardial inflammation and improved biventricular ejection fraction in a patient with giant cell arteritis.
Synapse has enriched 10 related papers. Consider them for comparative context: